Last reviewed · How we verify
NKG2D CAR-NK Cell Therapy for Patients With Platinum-Resistant Recurrent Ovarian Cancer
This trial will explore the maximum tolerated dose （MTD）of NKG2D CAR-NK cells in the treatment of platinum-resistant, relapsed epithelial ovarian cancer in a dose-escalation manner, and observe the clinical safety and efficacy.
Details
| Lead sponsor | Hangzhou Cheetah Cell Therapeutics Co., Ltd |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 18 |
| Start date | 2023-03 |
| Completion | 2024-09 |
Conditions
- Ovarian Cancer
Interventions
- NKG2D CAR-NK
Primary outcomes
- DLT — 28 days
Dose-Limiting Toxicity - MTD — 28 days
Maximal Tolerable Dose
Countries
China